Physician profile
Terence David Sanger
NPI 1326036013
$72,708.55
in general payments reported to CMS, 2019-2025
7 companies · $220 in 2025
The $220 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1.79 · 2021: $12K · 2022: $48K · 2023: $12K · 2024: $116 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $525 · Travel and Lodging: $14.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,000.00 |
| Food and Beverage | $525.03 |
| Travel and Lodging | $14.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cala Health, INC. | $72,000.00 | 2021-2023 | Cala Trio |
| Medtronic, INC. | $608.14 | 2022-2025 | Activa Pc, Percept Pc Brainsense |
| Ipsen Biopharmaceuticals, INC | $27.96 | 2023 | Dysport |
| Abbvie INC. | $25.08 | 2023 | Botox |
| Abbott Laboratories | $24.54 | 2024 | Infinity |
| Neuropace, INC. | $18.55 | 2024 | |
| Travere Therapeutics, INC. | $4.28 | 2020-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$120,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terence Sanger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.